Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 3/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.43 |
| ▸ | RXRG | P48443 | 2/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 8/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7618833 | 0.84 | HCAR3 (0.47) | RXRARXRBRXRGRARARARB | |
| SCHEMBL7711926 | 0.84 | ESRRA (0.36) | CA1CA2 | |
| SCHEMBL8722093 | 0.83 | MAPT (0.47) | SRD5A2 | |
| SCHEMBL7715738 | 0.83 | CA1 (0.44) | MCL1CA1CA2 | |
| SCHEMBL8722150 | 0.80 | CA2 (0.42) | CA2 | |
| SCHEMBL8726548 | 0.80 | ALDH1A1 (0.43) | CA1CA2 | |
| SCHEMBL7711919 | 0.79 | EGFR (0.52) | PARP15PARP10SRD5A2CA1CA2 | |
| SCHEMBL7717390 | 0.77 | MAPT (0.36) | MCL1CA1 | |
| SCHEMBL8722107 | 0.76 | PYGL (0.36) | CA1CA2 | |
| Alkyrom SCHEMBL11412605 | 0.76 | ALDH1A1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436691-B1 | CONJUGATE WHICH IS SUBSTANTIALLY NON-IMMUNOGENIC IN HUMANS COMPRISING TARGETING MOIETY CAPABLE OF BINDING WITH TUMOR ASSOCIATED ANTIGEN LINKED TO MUTATED FORM OF CARBOXYPEPTIDASE B ENZYME CAPABLE OF CONVERTING PRODRUG INTO ANTICANCER DRUG | ZENECA LIMITED (GB) | 2002-08-20 | — | — | US | disclosed |
| WO-1998035982-A1 | COMPOUNDS FOR USE IN ADEPT | ZENECA LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| EP-0844885-A2 | CHEMICAL COMPOUNDS | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997007769-A2 | CHEMICAL COMPOUNDS | ZENECA LIMITED (GB) | 1997-03-06 | — | — | WO | disclosed |